DELBERT-LABORATORIES
18.11.2022 15:30:37 CET | Business Wire | Press release
DELBERT Laboratories are proud to announce the acquisition from Noventia Pharma Srl of the European MA of CEPLENE® 0.5mg/0.5ml, solution for injection (histamine dihydrochloride) on September 12, 2022, and strengthens its commitment in hematology-oncology in Europe.
Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study published in Blood in 2006 and received orphan drug designation in 2005 1,2,3.
Acute myeloid leukemias are rare genetic diseases. In Europe, the incidence is estimated at 3.7/100,000 new cases per year. The prognosis for AML is unfavourable with a 5-year relative survival rate of 19%4.
DELBERT Laboratories (https://laboratoires-delbert.fr/) is a French pharmaceutical company specialized in the "renewal of essential medicines" frequently affected by marketing termination, stock shortages, particularly in times of crisis.
"We are focused on keeping essential medicines available to patients in 3 therapeutic areas (Antiinfectives, CNS and Oncology), with the mission of maintaining the therapeutic arsenal of doctors and preventing well-balanced patients from changing treatments.The acquisition of Ceplene's® MA in Europe is part of this strategy to maintain essential medicines and make available medicines with clinical benefit in rare diseases," said Eric Fidelin (Head of Strategy & Global Development).
With this acquisition, DELBERT Laboratories strengthens its presence in hematological oncology.
About DELBERT Laboratories
The mission of DELBERT Laboratories is to maintain access to Drugs of Major Therapeutic Interest for patients. Every year, Delbert Laboratories acquires new drugs whose future is compromised.
DELBERT Laboratories focuses its efforts on finding production sites in Europe. With their collaborators and the support of clinicians, galenicians, engineers and chemists, DELBERT Laboratories are reviving these drugs in order to guarantee their availability to the medical profession and patients.
DELBERT Laboratories will reach more than €30m in turnover in 2022 with double-digit growth each year and already markets 14 products (including 13 originators) with hospital or specialists reserved prescriptions.
DELBERT Laboratories financed this acquisition thanks to trusting relationships with their financial partners who strongly support these values focused on patient access to Drugs of Major Therapeutic Interest.
http://www.laboratoires-delbert.fr/
References:
1. Brune et al., Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood, 1 july 2006 volume 108, number 1, 88-96
2. Nilsson, Malin S., et al. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia. British Journal of Haematology 188.4 (2020): e49
3. Ceplene® Epar, 2008 - EMEA/H/C/000796
4. Visser et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012 Nov;48(17):3257-66.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DATA and Cursor Partner to Accelerate Enterprise-Grade Modernization and AI Governance24.6.2026 14:00:00 CEST | Press release
NTT DATA leveraging Cursor to strengthen its own engineering and delivery model. Enterprise-grade governance helps modernize and transform delivery with greater trust and control. NTT DATA, a global leader in AI, digital business and technology services, today announced a strategic partnership with Cursor, the leading multi-model AI coding platform. Under this initiative, NTT DATA will use Cursor’s advanced AI agents to power the innovation of its global software engineering and delivery models. Cursor will enable NTT DATA to design, build and modernize enterprise systems with greater speed and control, while supporting the governance enterprises require. The collaboration marks a strategic advancement in NTT DATA’s transformation into an AI-native services company, enhancing how the company designs, builds and modernizes mission-critical systems. NTT DATA is operationalizing AI inside its engineering and delivery engine with enterprise-grade controls to enable faster modernization of
Carnegie Mellon Team Awarded ARPA-H Contract to Transform Care During Labor and Childbirth24.6.2026 13:05:00 CEST | Press release
New wearable monitoring system will improve clinical assessment of fetal health Carnegie Mellon University is leading a multi-university team that has secured an award of up to $39.3 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop a wearable monitoring system to better identify fetal distress and its cause, enabling a safer labor and delivery experience for mothers and babies. The system, called OMEGA, or Optical, Mechanical, and Electrical Global Assessment of fetal hypoxia, aims to replace 50-year old, indirect, unreliable fetal heart rate monitoring technology with a unified, real-time assessment of fetal oxygen delivery and adaptive capacity. The project is under ARPA-H’s Making Obstetric Care Smart program, which is led by ARPA-H Program Manager Kate Arnold, M.D., MBA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624524685/en/ Carnegie Mellon University is leading a multi-universit
€243B Tech Spend Ahead, but Only 1 in 4 Firms Achieves Scale: WBAM Research Reveals Structural Paradox24.6.2026 12:28:00 CEST | Press release
Research report by Monitor Deloitte and Objectway investigates how and why as-a-service models are gaining ground, and what separates successful execution from failed implementation.Key takeaways Firms are layering resources onto legacy, widening the gap between investment intensity and operational scalability Technology investment alone is insufficient. The real differentiator lies in how Tech&Ops capabilities are sourced, orchestrated, and delivered As-a-service adoption is set to triple in the next 2–3 years, emerging as a key lever to unlock scale According to research conducted by Monitor Deloitte, a consultancy firm, and Objectway, a growth partner for the financial services industry, wealth, banking and asset management (WBAM) firms are investing at record levels, with Technology & Operations spending reaching €173 billion globally and set to hit €243 billion by 2029. However, yet only around one in four firms has achieved true front-to-back scalability, growing their business w
PUMA Dominates HYROX World Championships From Elite Athlete Performances to Community Initiatives24.6.2026 12:15:00 CEST | Press release
Global sports brand PUMA continued its HYROX dominance at the 2026 HYROX World Championships with a host of standout elite athlete performances and iconic community moments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624897869/en/ Global sports brand PUMA continued its HYROX dominance at the 2026 HYROX World Championships with a host of standout elite athlete performances and iconic community moments, including Jake Williamson (left) and Hunter McIntyre in the Men’s Elite15 Doubles. Leading the charge was Jess Pettrow, who won the Mixed Relay with Australia for the second year in a row, with the team defending their title with an epic time of 50:19. Pettrow’s golden moment followed a fourth place finish with partner Joanna Wietrzyk in the Women’s Elite 15 Doubles, making it a highly successful weekend for the PUMA athlete. In addition to her strong showing in the Women’s Elite Doubles, Australian athlete Wietrzyk also
Rockstar Games Announces Pre-Orders for Grand Theft Auto VI24.6.2026 12:15:00 CEST | Press release
Starting at Midnight Local Time on June 25, 2026 Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is excited to announce that pre-orders for Grand Theft Auto VI will begin on June 25, 2026, at midnight local time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624539426/en/ Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is excited to announce that pre-orders for Grand Theft Auto VI will begin on June 25, 2026, at midnight local time. Launching November 19, 2026, for the PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems for $79.99, Grand Theft Auto VI features a single-player experience set in the biggest, most immersive evolution of the series yet. Launching November 19, 2026, for the PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems for $79.9
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom